We are analyzing https://link.springer.com/article/10.1186/2055-0928-1-7.

Title:
Weekly cholecalciferol supplementation results in significant reductions in infection risk among the vitamin D deficient: results from the CIPRIS pilot RCT | BMC Nutrition
Description:
Observational studies suggest vitamin D deficiency may contribute to the risk of acute infections. We undertook a randomised controlled trial (RCT) of cholecalciferol supplementation as an intervention against acute infections. A cohort of 34 healthy adults was randomised to 20,000 IU/week cholecalciferol or identical placebo and followed for 17 weeks during winter 2012. Acute infections, defined as the occurrence of sustained (at least an hour) infection symptoms, either of severity 2/5 or greater or sustained over 24 h, were monitored by daily online symptom reporting, with potential infections assessed in clinic. No microbiological verification of symptoms was available, however. Primary endpoint was the occurrence of acute infection; secondary endpoints were infection duration and infection severity; and tertiary endpoints were change in serum 25-hydroxyvitamin D (25(OH)D) and adverse events. No treatment effect was observed for infection risk (HR: 0.83, 95% CI: 0.53, 1.31), nor duration or severity. However, on stratification by baseline serum 25(OH)D (levels chosen on the basis of average levels in our cohort and known minimums needed for bone health), a significant treatment effect on infection risk was evident among those who were vitamin D deficient at the start of the study, such that those of baseline 25(OH)D < 40 nmol/L (n = 4) realised a 44% reduction in infection risk (HR: 0.56; 95% CI: 0.32, 0.96; P = 0.007), this increasing to 73% on restriction to clinically verified infections (HR: 0.27; 95% CI: 0.07, 1.00; P = 0.050). A similar but less consistent and nonsignificant effect was seen for infection severity. Treatment was associated with significantly higher 25(OH)D compared to placebo; however, the maximum 25(OH)D was 154 nmol/L and no adverse events occurred. The results of this study suggest a protective effect of vitamin D supplementation against acute infection risk among persons who are vitamin D deficient. Larger studies are needed to validate these findings.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Science
Education
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,626,432 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't see how the site brings in money.

Not every website is profit-driven; some are created to spread information or serve as an online presence. Websites can be made for many reasons. This could be one of them. Link.springer.com could have a money-making trick up its sleeve, but it's undetectable for now.

Keywords {🔍}

infection, vitamin, treatment, infections, article, pubmed, ohd, study, effect, google, scholar, severity, respiratory, participants, cas, acute, supplementation, symptoms, serum, significant, data, cholecalciferol, clinic, duration, placebo, deficient, trial, tract, results, risk, reported, nmoll, research, cohort, baseline, healthy, adults, daily, symptom, assessed, protective, information, randomised, persons, shown, followup, table, bmi, central, occurrence,

Topics {✒️}

pre-publication history nf-kappab-linked chemokines multiple sclerosis patients camargo ca jr kruskal-wallis rank test article download pdf steve simpson jr open access license vitamin d-dependent mechanism nutrition examination survey prevent seasonal influenza privacy choices/manage cookies full size image 000 iu/week cholecalciferol supplementation daily online surveys double-blind intervention study related subjects online daily questionnaire randomised controlled trials respiratory viral infections double-blind rct anti-viral state article simpson respiratory virus infections van der mei inter-review interval duration randomised controlled trial chronic respiratory condition respiratory tract infection provide informed consent antimicrobial peptide expression respiratory tract infections weekly cholecalciferol supplementation innate immune system regulate antimicrobial peptides march-june 2012 conducted online questionnaire responses acute respiratory infection randomized controlled trials cipris pilot rct tandem mass spectroscopy proportional hazard assumption royal hobart hospital full access daily online follow high-dose cholecalciferol chronic underlying conditions initial manuscript draft acute phase reactants randomized controlled trial

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Weekly cholecalciferol supplementation results in significant reductions in infection risk among the vitamin D deficient: results from the CIPRIS pilot RCT
         description:Observational studies suggest vitamin D deficiency may contribute to the risk of acute infections. We undertook a randomised controlled trial (RCT) of cholecalciferol supplementation as an intervention against acute infections. A cohort of 34 healthy adults was randomised to 20,000 IU/week cholecalciferol or identical placebo and followed for 17 weeks during winter 2012. Acute infections, defined as the occurrence of sustained (at least an hour) infection symptoms, either of severity 2/5 or greater or sustained over 24 h, were monitored by daily online symptom reporting, with potential infections assessed in clinic. No microbiological verification of symptoms was available, however. Primary endpoint was the occurrence of acute infection; secondary endpoints were infection duration and infection severity; and tertiary endpoints were change in serum 25-hydroxyvitamin D (25(OH)D) and adverse events. No treatment effect was observed for infection risk (HR: 0.83, 95% CI: 0.53, 1.31), nor duration or severity. However, on stratification by baseline serum 25(OH)D (levels chosen on the basis of average levels in our cohort and known minimums needed for bone health), a significant treatment effect on infection risk was evident among those who were vitamin D deficient at the start of the study, such that those of baseline 25(OH)D < 40 nmol/L (n = 4) realised a 44% reduction in infection risk (HR: 0.56; 95% CI: 0.32, 0.96; P = 0.007), this increasing to 73% on restriction to clinically verified infections (HR: 0.27; 95% CI: 0.07, 1.00; P = 0.050). A similar but less consistent and nonsignificant effect was seen for infection severity. Treatment was associated with significantly higher 25(OH)D compared to placebo; however, the maximum 25(OH)D was 154 nmol/L and no adverse events occurred. The results of this study suggest a protective effect of vitamin D supplementation against acute infection risk among persons who are vitamin D deficient. Larger studies are needed to validate these findings.
         datePublished:2015-03-09T00:00:00Z
         dateModified:2015-03-09T00:00:00Z
         pageStart:1
         pageEnd:10
         license:http://creativecommons.org/publicdomain/zero/1.0/
         sameAs:https://doi.org/10.1186/2055-0928-1-7
         keywords:
            Vitamin D
            Acute infection
            Randomised controlled trial
            Clinical Nutrition
            Health Promotion and Disease Prevention
            Public Health
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F2055-0928-1-7/MediaObjects/40795_2014_7_Fig1_HTML.jpg
         isPartOf:
            name:BMC Nutrition
            issn:
               2055-0928
            volumeNumber:1
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Steve Simpson
               affiliation:
                     name:University of Tasmania
                     address:
                        name:Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Ingrid van der Mei
               affiliation:
                     name:University of Tasmania
                     address:
                        name:Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Niall Stewart
               affiliation:
                     name:University of Tasmania
                     address:
                        name:School of Pharmacy, University of Tasmania, Hobart, Australia
                        type:PostalAddress
                     type:Organization
                     name:University of Tasmania
                     address:
                        name:School of Medicine, University of Tasmania, Hobart, Australia
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Leigh Blizzard
               affiliation:
                     name:University of Tasmania
                     address:
                        name:Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Prudence Tettey
               affiliation:
                     name:University of Tasmania
                     address:
                        name:Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Bruce Taylor
               affiliation:
                     name:University of Tasmania
                     address:
                        name:Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Weekly cholecalciferol supplementation results in significant reductions in infection risk among the vitamin D deficient: results from the CIPRIS pilot RCT
      description:Observational studies suggest vitamin D deficiency may contribute to the risk of acute infections. We undertook a randomised controlled trial (RCT) of cholecalciferol supplementation as an intervention against acute infections. A cohort of 34 healthy adults was randomised to 20,000 IU/week cholecalciferol or identical placebo and followed for 17 weeks during winter 2012. Acute infections, defined as the occurrence of sustained (at least an hour) infection symptoms, either of severity 2/5 or greater or sustained over 24 h, were monitored by daily online symptom reporting, with potential infections assessed in clinic. No microbiological verification of symptoms was available, however. Primary endpoint was the occurrence of acute infection; secondary endpoints were infection duration and infection severity; and tertiary endpoints were change in serum 25-hydroxyvitamin D (25(OH)D) and adverse events. No treatment effect was observed for infection risk (HR: 0.83, 95% CI: 0.53, 1.31), nor duration or severity. However, on stratification by baseline serum 25(OH)D (levels chosen on the basis of average levels in our cohort and known minimums needed for bone health), a significant treatment effect on infection risk was evident among those who were vitamin D deficient at the start of the study, such that those of baseline 25(OH)D < 40 nmol/L (n = 4) realised a 44% reduction in infection risk (HR: 0.56; 95% CI: 0.32, 0.96; P = 0.007), this increasing to 73% on restriction to clinically verified infections (HR: 0.27; 95% CI: 0.07, 1.00; P = 0.050). A similar but less consistent and nonsignificant effect was seen for infection severity. Treatment was associated with significantly higher 25(OH)D compared to placebo; however, the maximum 25(OH)D was 154 nmol/L and no adverse events occurred. The results of this study suggest a protective effect of vitamin D supplementation against acute infection risk among persons who are vitamin D deficient. Larger studies are needed to validate these findings.
      datePublished:2015-03-09T00:00:00Z
      dateModified:2015-03-09T00:00:00Z
      pageStart:1
      pageEnd:10
      license:http://creativecommons.org/publicdomain/zero/1.0/
      sameAs:https://doi.org/10.1186/2055-0928-1-7
      keywords:
         Vitamin D
         Acute infection
         Randomised controlled trial
         Clinical Nutrition
         Health Promotion and Disease Prevention
         Public Health
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F2055-0928-1-7/MediaObjects/40795_2014_7_Fig1_HTML.jpg
      isPartOf:
         name:BMC Nutrition
         issn:
            2055-0928
         volumeNumber:1
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Steve Simpson
            affiliation:
                  name:University of Tasmania
                  address:
                     name:Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Ingrid van der Mei
            affiliation:
                  name:University of Tasmania
                  address:
                     name:Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Niall Stewart
            affiliation:
                  name:University of Tasmania
                  address:
                     name:School of Pharmacy, University of Tasmania, Hobart, Australia
                     type:PostalAddress
                  type:Organization
                  name:University of Tasmania
                  address:
                     name:School of Medicine, University of Tasmania, Hobart, Australia
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Leigh Blizzard
            affiliation:
                  name:University of Tasmania
                  address:
                     name:Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Prudence Tettey
            affiliation:
                  name:University of Tasmania
                  address:
                     name:Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Bruce Taylor
            affiliation:
                  name:University of Tasmania
                  address:
                     name:Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:BMC Nutrition
      issn:
         2055-0928
      volumeNumber:1
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University of Tasmania
      address:
         name:Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia
         type:PostalAddress
      name:University of Tasmania
      address:
         name:Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia
         type:PostalAddress
      name:University of Tasmania
      address:
         name:School of Pharmacy, University of Tasmania, Hobart, Australia
         type:PostalAddress
      name:University of Tasmania
      address:
         name:School of Medicine, University of Tasmania, Hobart, Australia
         type:PostalAddress
      name:University of Tasmania
      address:
         name:Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia
         type:PostalAddress
      name:University of Tasmania
      address:
         name:Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia
         type:PostalAddress
      name:University of Tasmania
      address:
         name:Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Steve Simpson
      affiliation:
            name:University of Tasmania
            address:
               name:Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Ingrid van der Mei
      affiliation:
            name:University of Tasmania
            address:
               name:Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia
               type:PostalAddress
            type:Organization
      name:Niall Stewart
      affiliation:
            name:University of Tasmania
            address:
               name:School of Pharmacy, University of Tasmania, Hobart, Australia
               type:PostalAddress
            type:Organization
            name:University of Tasmania
            address:
               name:School of Medicine, University of Tasmania, Hobart, Australia
               type:PostalAddress
            type:Organization
      name:Leigh Blizzard
      affiliation:
            name:University of Tasmania
            address:
               name:Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia
               type:PostalAddress
            type:Organization
      name:Prudence Tettey
      affiliation:
            name:University of Tasmania
            address:
               name:Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia
               type:PostalAddress
            type:Organization
      name:Bruce Taylor
      affiliation:
            name:University of Tasmania
            address:
               name:Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia
      name:Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia
      name:School of Pharmacy, University of Tasmania, Hobart, Australia
      name:School of Medicine, University of Tasmania, Hobart, Australia
      name:Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia
      name:Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia
      name:Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia

External Links {🔗}(153)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Foundation
Prism.js

CDN Services {📦}

Crossref

4.91s.

LINK . SPRINGER . COM {}